Bruno Martins Tomazini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bruno Martins Tomazini has a total of 296 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Biasi Cavalcanti
Brazilian Research in Intensive Care Network (BRICNet) - São Paulo (SP), Brazil
14 shared publications - Viviane Cordeiro Veiga
Brazilian Research in Intensive Care Network (BRICNet), São Paulo, SP, Brazil
14 shared publications - Bruno Adler Maccagnan Pinheiro Besen
Fundação Antonio Prudente-A C Camargo Cancer Center, São Paulo, SP, Brazil
13 shared publications - Antonio Paulo Nassar Junior
Intensive Care Unit, AC Camargo Cancer Center, São Paulo, Brazil
8 shared publications - Adriano José Pereira
Hospital Israelita Albert Einstein - São Paulo (SP), Brazil
7 shared publications - Israel Silva Maia
Research Institute, HCor-Hospital do Coração - São Paulo (SP), Brazil
7 shared publications
Latest Publications
- 19 October 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
Infections Acquired in the ICU Among Cancer and Other Immunosuppressed Patients: A Nationwide Cohort Study
Objectives: To compare the cumulative incidence of ICU-acquired infections (ICU-AIs) across distinct immunosuppression diagnostic categories (solid cancer, hematological cancer, other immunosuppression) and nonimmunosuppressed patients, accounting for competing risks of death and discharge. Design: Retrospective cohort study using prospectively collected data. Setting: A total of 50 participating ICUs in Brazil. Patients: A total of 38,126 adult patients admitted between October 2019 and December 2021 with an ICU stay exceeding 48 hours and no infections diagnosed within the first 48 hours. Interventions: None. Measurements and Main Results: The primary outcome was the incidence of the first ICU-AI during the ICU stay, evaluated using Fine-Gray subdistribution hazard ratios (sHR). In the multivariable competing-risk analysis, patients with hematological malignancies (sHR, 1.64; 95% CI, 1.01–2.65) and other immunosuppressive conditions (sHR, 1.61; 95% CI, 1.02–2.54) were associated with an increased cumulative incidence of ICU-AI, while solid malignancy was not significantly different from non-immunosuppressed patients (sHR, 0.88; 95% CI, 0.68–1.14). Conclusions: Patients with hematological malignancies and other immunosuppressive conditions face a significantly higher risk of ICU-AIs.
- 19 October 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
Infections Acquired in the ICU Among Cancer and Other Immunosuppressed Patients: A Nationwide Cohort Study
Objectives: To compare the cumulative incidence of ICU-acquired infections (ICU-AIs) across distinct immunosuppression diagnostic categories (solid cancer, hematological cancer, other immunosuppression) and nonimmunosuppressed patients, accounting for competing risks of death and discharge. Design: Retrospective cohort study using prospectively collected data. Setting: A total of 50 participating ICUs in Brazil. Patients: A total of 38,126 adult patients admitted between October 2019 and December 2021 with an ICU stay exceeding 48 hours and no infections diagnosed within the first 48 hours. Interventions: None. Measurements and Main Results: The primary outcome was the incidence of the first ICU-AI during the ICU stay, evaluated using Fine-Gray subdistribution hazard ratios (sHR). In the multivariable competing-risk analysis, patients with hematological malignancies (sHR, 1.64; 95% CI, 1.01–2.65) and other immunosuppressive conditions (sHR, 1.61; 95% CI, 1.02–2.54) were associated with an increased cumulative incidence of ICU-AI, while solid malignancy was not significantly different from non-immunosuppressed patients (sHR, 0.88; 95% CI, 0.68–1.14). Conclusions: Patients with hematological malignancies and other immunosuppressive conditions face a significantly higher risk of ICU-AIs.
- Open Access
- 3 June 2026
- Published by Springer Nature in Research Integrity and Peer Review
- Vol. 11 (1)
Susceptibility of large language models to hidden nudge injection during simulated medical peer review: a quasi-experimental study
Background: Generative artificial intelligence (AI) technologies might offer new possibilities for the peer review process; however, AI models' possible vulnerability to hidden nudges designed to elicit positive reviews raises concerns about manipulation susceptibility, which remains unexplored. We aimed to evaluate AI model susceptibility to hidden nudges in peer review. Methods: This quasi-experimental study was conducted between July and December 2025. Four commercial AI models were evaluated simultaneously: GPT-4 (OpenAI), Gemini 2.5 Flash (Google), DeepSeek-V3 (DeepSeek), and Claude Opus 4 (Anthropic). We used 90 pre-print and 90 published manuscripts in critical care and cardiology to feed the AI models. All manuscripts were converted to individual Microsoft Word files, with identifying information removed, to mimic a manuscript submitted to a journal for peer review. Each manuscript underwent three independent evaluations per model using standardized prompts requesting evaluation and recommendation on whether to accept or reject it for publication. First, we evaluated the manuscript without any nudge. Second, we inserted a hidden nudge opposing the initial recommendation (e.g., a negative nudge if initially accepted). Finally, we evaluated the nudged manuscripts using a modified prompt warning about potential hidden nudges. All recommendations were categorized as accept or reject. The main outcomes were the change rates in recommendations after nudge insertion compared to initial recommendations, and after nudge insertion with the modified prompt, analyzed separately for each AI model. Results: Across all AI models tested, nudge insertion led to a change in the recommendation in 84.4% of the time (608/720), with Deepseek being the most susceptible model (100% of change), followed by Gemini (97.8% of change), Chat GPT (82.8% of change) and Claude (57.2% of change). Using a specific prompt to warn AI models about potential malicious nudge injections in the manuscripts did not substantially alter the results. Recommendations were still modified in 76.8% of cases (553/720). Conclusions: In this quasi-experimental study, all tested AI models were highly susceptible to hidden nudge insertions in manuscripts during simulated peer review. Importantly, explicitly warning AI models about potential nudge injections does not meaningfully reduce their susceptibility to manipulation.
- 3 June 2026
- Published by Springer Nature in Research Integrity and Peer Review
- Vol. 11 (1)
Open AccessSusceptibility of large language models to hidden nudge injection during simulated medical peer review: a quasi-experimental study
Background: Generative artificial intelligence (AI) technologies might offer new possibilities for the peer review process; however, AI models' possible vulnerability to hidden nudges designed to elicit positive reviews raises concerns about manipulation susceptibility, which remains unexplored. We aimed to evaluate AI model susceptibility to hidden nudges in peer review. Methods: This quasi-experimental study was conducted between July and December 2025. Four commercial AI models were evaluated simultaneously: GPT-4 (OpenAI), Gemini 2.5 Flash (Google), DeepSeek-V3 (DeepSeek), and Claude Opus 4 (Anthropic). We used 90 pre-print and 90 published manuscripts in critical care and cardiology to feed the AI models. All manuscripts were converted to individual Microsoft Word files, with identifying information removed, to mimic a manuscript submitted to a journal for peer review. Each manuscript underwent three independent evaluations per model using standardized prompts requesting evaluation and recommendation on whether to accept or reject it for publication. First, we evaluated the manuscript without any nudge. Second, we inserted a hidden nudge opposing the initial recommendation (e.g., a negative nudge if initially accepted). Finally, we evaluated the nudged manuscripts using a modified prompt warning about potential hidden nudges. All recommendations were categorized as accept or reject. The main outcomes were the change rates in recommendations after nudge insertion compared to initial recommendations, and after nudge insertion with the modified prompt, analyzed separately for each AI model. Results: Across all AI models tested, nudge insertion led to a change in the recommendation in 84.4% of the time (608/720), with Deepseek being the most susceptible model (100% of change), followed by Gemini (97.8% of change), Chat GPT (82.8% of change) and Claude (57.2% of change). Using a specific prompt to warn AI models about potential malicious nudge injections in the manuscripts did not substantially alter the results. Recommendations were still modified in 76.8% of cases (553/720). Conclusions: In this quasi-experimental study, all tested AI models were highly susceptible to hidden nudge insertions in manuscripts during simulated peer review. Importantly, explicitly warning AI models about potential nudge injections does not meaningfully reduce their susceptibility to manipulation.
- 28 April 2026
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (7) , 1-8
Antimicrobial decision-making under uncertainty in the high-stakes intensive care unit scenario: a critical interpretative synthesis
Background: Antimicrobial Stewardship in the intensive care unit setting is a difficult task due to diagnostic uncertainty and perceived high-risk of poor outcomes in case of delayed or inappropriate treatment. Although novel diagnostics and other strategies have been proposed to improve antimicrobial use, their clinical effectiveness in real-world settings has been suboptimal. Methods: We designed a critical interpretative synthesis of the literature, which allows the combination of quantitative and qualitative studies to revise and critique concepts used in Antimicrobial Stewardship efforts in the ICU setting. We searched the literature in duplicate with a sensitive strategy to identify main concepts, and we developed a main theme and conceptual framework after identifying the main concepts and strategies. Results: After screening 41,192 titles and abstracts and reviewing 1,335 full-text manuscripts, we selected 29 main manuscripts for this synthesis. We identified that classical concepts, such as the use of broad-spectrum antibiotics followed by de-escalation and the use of biomarkers of infection and novel diagnostics, although with face validity and supported by efficacy studies, carry a high risk of being ineffective in real-world settings. We argue that this discrepancy is due to cognitive biases in antimicrobial decision-making in the ICU setting, including risk-aversion behavior, diagnostic momentum, premature closure, therapeutic momentum, hyperbolic discounting, commission bias, and anchoring bias, among others, which drive intensivists towards overdiagnosis and overtreatment of infection. Conclusions: Incorporation of the cognitive theory of decision-making in future stewardship efforts is necessary in the ICU setting along with traditional stewardship interventions.
- 28 April 2026
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (7) , 1-8
Antimicrobial decision-making under uncertainty in the high-stakes intensive care unit scenario: a critical interpretative synthesis
Background: Antimicrobial Stewardship in the intensive care unit setting is a difficult task due to diagnostic uncertainty and perceived high-risk of poor outcomes in case of delayed or inappropriate treatment. Although novel diagnostics and other strategies have been proposed to improve antimicrobial use, their clinical effectiveness in real-world settings has been suboptimal. Methods: We designed a critical interpretative synthesis of the literature, which allows the combination of quantitative and qualitative studies to revise and critique concepts used in Antimicrobial Stewardship efforts in the ICU setting. We searched the literature in duplicate with a sensitive strategy to identify main concepts, and we developed a main theme and conceptual framework after identifying the main concepts and strategies. Results: After screening 41,192 titles and abstracts and reviewing 1,335 full-text manuscripts, we selected 29 main manuscripts for this synthesis. We identified that classical concepts, such as the use of broad-spectrum antibiotics followed by de-escalation and the use of biomarkers of infection and novel diagnostics, although with face validity and supported by efficacy studies, carry a high risk of being ineffective in real-world settings. We argue that this discrepancy is due to cognitive biases in antimicrobial decision-making in the ICU setting, including risk-aversion behavior, diagnostic momentum, premature closure, therapeutic momentum, hyperbolic discounting, commission bias, and anchoring bias, among others, which drive intensivists towards overdiagnosis and overtreatment of infection. Conclusions: Incorporation of the cognitive theory of decision-making in future stewardship efforts is necessary in the ICU setting along with traditional stewardship interventions.
- Open Access
- 27 April 2026
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38, e20260322
Surveys in clinical research: methodological aspects and practical guidance
Use of surveys in clinical research allows investigators to explore stakeholders’ perspectives, measure implementation of interventions, and inform future decision-making. Surveys are versatile and accessible, but they require methodological rigor to yield adequate results. Their development involves a sequence of decisions that influence both data quality and interpretability – from defining objectives and selecting […] ABSTRACT Use of surveys in clinical research allows investigators to explore stakeholders’ perspectives, measure implementation of interventions, and inform future decision-making. Surveys are versatile and accessible, but they require methodological rigor to yield adequate results. Their development involves a sequence of decisions that influence both data quality and interpretability – from defining objectives and selecting […]
- 27 April 2026
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38, e20260322
Open AccessSurveys in clinical research: methodological aspects and practical guidance
Use of surveys in clinical research allows investigators to explore stakeholders’ perspectives, measure implementation of interventions, and inform future decision-making. Surveys are versatile and accessible, but they require methodological rigor to yield adequate results. Their development involves a sequence of decisions that influence both data quality and interpretability – from defining objectives and selecting […] ABSTRACT Use of surveys in clinical research allows investigators to explore stakeholders’ perspectives, measure implementation of interventions, and inform future decision-making. Surveys are versatile and accessible, but they require methodological rigor to yield adequate results. Their development involves a sequence of decisions that influence both data quality and interpretability – from defining objectives and selecting […]
- Open Access
- 12 February 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 56, 101400
Daily Chlorhexidine Bathing for the Prevention of Nosocomial Infections in Critically Ill Patients (CLEAN-IT): a multicentre, cluster-randomised, crossover trial
- 12 February 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 56, 101400
Open AccessDaily Chlorhexidine Bathing for the Prevention of Nosocomial Infections in Critically Ill Patients (CLEAN-IT): a multicentre, cluster-randomised, crossover trial
- Open Access
- 1 July 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 37, e20250319
Organosilane for surface cleaning in intensive care units: protocol for a cluster randomized controlled trial with crossover
Objective: To assess whether surface disinfection with organosilane in the intensive care unit reduces the occurrence of healthcare-associated infections. Methods: This multicenter, controlled, cluster-randomized trial includes 14 intensive care units in Brazil from November 2023 to December 2024. The local hygiene team of the included intensive care units will disinfect bed surfaces with organosilane […] ABSTRACT Objective: To assess whether surface disinfection with organosilane in the intensive care unit reduces the occurrence of healthcare-associated infections. Methods: This multicenter, controlled, cluster-randomized trial includes 14 intensive care units in Brazil from November 2023 to December 2024. The local hygiene team of the included intensive care units will disinfect bed surfaces with organosilane […]
- 1 July 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 37, e20250319
Open AccessOrganosilane for surface cleaning in intensive care units: protocol for a cluster randomized controlled trial with crossover
Objective: To assess whether surface disinfection with organosilane in the intensive care unit reduces the occurrence of healthcare-associated infections. Methods: This multicenter, controlled, cluster-randomized trial includes 14 intensive care units in Brazil from November 2023 to December 2024. The local hygiene team of the included intensive care units will disinfect bed surfaces with organosilane […] ABSTRACT Objective: To assess whether surface disinfection with organosilane in the intensive care unit reduces the occurrence of healthcare-associated infections. Methods: This multicenter, controlled, cluster-randomized trial includes 14 intensive care units in Brazil from November 2023 to December 2024. The local hygiene team of the included intensive care units will disinfect bed surfaces with organosilane […]
- Open Access
- 4 June 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 37, e20250284
Brazilian Research in Intensive Care Network (BRICNet): shaping the landscape of critical care research in Brazil and beyond
Critical illnesses such as sepsis and acute respiratory distress syndrome lead to millions of deaths globally, with a higher burden in low- and middle-income countries. Conducting multicentric clinical studies is essential to help minimize the burden of critical illnesses, particularly in areas where their impact is greater. However, conducting large-scale multicentric studies is challenging, […] ABSTRACT Critical illnesses such as sepsis and acute respiratory distress syndrome lead to millions of deaths globally, with a higher burden in low- and middle-income countries. Conducting multicentric clinical studies is essential to help minimize the burden of critical illnesses, particularly in areas where their impact is greater. However, conducting large-scale multicentric studies is challenging, […]
- 4 June 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 37, e20250284
Open AccessBrazilian Research in Intensive Care Network (BRICNet): shaping the landscape of critical care research in Brazil and beyond
Critical illnesses such as sepsis and acute respiratory distress syndrome lead to millions of deaths globally, with a higher burden in low- and middle-income countries. Conducting multicentric clinical studies is essential to help minimize the burden of critical illnesses, particularly in areas where their impact is greater. However, conducting large-scale multicentric studies is challenging, […] ABSTRACT Critical illnesses such as sepsis and acute respiratory distress syndrome lead to millions of deaths globally, with a higher burden in low- and middle-income countries. Conducting multicentric clinical studies is essential to help minimize the burden of critical illnesses, particularly in areas where their impact is greater. However, conducting large-scale multicentric studies is challenging, […]
- Open Access
- 3 January 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-9
Clinical impact of healthcare-associated infections in Brazilian ICUs: a multicenter prospective cohort
Limited data is available to evaluate the burden of device associated healthcare infections (HAI) [central line associated bloodstream infection (CLABSI), catheter associated urinary tract infection (CAUTI), and ventilator associated pneumonia (VAP)] in low and-middle-income countries. Our aim is to investigate the population attributable mortality fraction and the absolute mortality difference of HAI in a broad population of critically ill patients from Brazil. Multicenter cohort study from September 2019 to December 2023 with prospective individual patient data collection. VAP, CLABSI, and CAUTI were diagnosed by each center in accordance with Brazilian regulatory agency guidance. If a patient fulfilled all diagnostic criteria, he was deemed to have Confirmed HAI. An adjusted disability multistate model was used to evaluate the population attributable in-hospital mortality fraction (PAF) and the absolute in-hospital mortality difference (AMD). A total of 128,247 patients were included. 4066 (3.2%) distinct patients had at least one diagnosis of HAI (1493 CLABSI, 433 CAUTI, 2742 VAP, and 435 patients with more than one HAI) during the ICU stay. The PAF was 3.89% (95% CI 3.68–4.11%) for HAI, 2.16% (2.05–2.33%) for VAP, 1.2% (1.08–1.32%) for CLABSI, 0.11% (0.07–0.16%) for CAUTI, and 0.33% (0.26–0.4%) for ≥ 2 HAI. The AMD for HAI was 33.69% (95% CI 32.27–35.33%), 29.01% (27.15–30.98%) for VAP, 31.64% (29.3–34.81%) for CLABSI, 9.94% (3.88–15.54%) for CAUTI and 35.6% (28.93–42.99%) for ≥ 2 HAI. Device-associated HAI significantly contribute to hospital mortality and impose a high excess risk of death for critically ill patients.
- 3 January 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-9
Open AccessClinical impact of healthcare-associated infections in Brazilian ICUs: a multicenter prospective cohort
Limited data is available to evaluate the burden of device associated healthcare infections (HAI) [central line associated bloodstream infection (CLABSI), catheter associated urinary tract infection (CAUTI), and ventilator associated pneumonia (VAP)] in low and-middle-income countries. Our aim is to investigate the population attributable mortality fraction and the absolute mortality difference of HAI in a broad population of critically ill patients from Brazil. Multicenter cohort study from September 2019 to December 2023 with prospective individual patient data collection. VAP, CLABSI, and CAUTI were diagnosed by each center in accordance with Brazilian regulatory agency guidance. If a patient fulfilled all diagnostic criteria, he was deemed to have Confirmed HAI. An adjusted disability multistate model was used to evaluate the population attributable in-hospital mortality fraction (PAF) and the absolute in-hospital mortality difference (AMD). A total of 128,247 patients were included. 4066 (3.2%) distinct patients had at least one diagnosis of HAI (1493 CLABSI, 433 CAUTI, 2742 VAP, and 435 patients with more than one HAI) during the ICU stay. The PAF was 3.89% (95% CI 3.68–4.11%) for HAI, 2.16% (2.05–2.33%) for VAP, 1.2% (1.08–1.32%) for CLABSI, 0.11% (0.07–0.16%) for CAUTI, and 0.33% (0.26–0.4%) for ≥ 2 HAI. The AMD for HAI was 33.69% (95% CI 32.27–35.33%), 29.01% (27.15–30.98%) for VAP, 31.64% (29.3–34.81%) for CLABSI, 9.94% (3.88–15.54%) for CAUTI and 35.6% (28.93–42.99%) for ≥ 2 HAI. Device-associated HAI significantly contribute to hospital mortality and impose a high excess risk of death for critically ill patients.
- Open Access
- 18 December 2024
- Published by Springer Nature in Critical Care
- Vol. 28 (1) , 1-12
Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial
Shorter courses of antimicrobial therapy have been shown to be non-inferior to longer durations for the management of several infections. However, data on critically ill patients with severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB) are scarce. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we assessed the non-inferiority of 7-day versus 14-day antimicrobial therapy for patients with intensive care unit (ICU)-acquired severe infections by MDR-GNB. This was a randomised multicenter, open-label, parallel controlled, non-inferiority trial. Adult patients with severe infections by MDR-GNB initiated ≥ 48 h of ICU admission were eligible if they were hemodynamically stable and without fever > 48 h on the 7th day of appropriate antimicrobial therapy. Patients were 1:1 randomised to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14 (± 1) days. The primary outcome was clinical failure, defined as death or relapse of infection within 28 days of randomisation. An upper edge of the two-tailed 95% confidence interval (CI) of the delta between the clinical failure rate in the 7- and the 14-day lower than 10% in both intention-to-treat (ITT) and per protocol (PP) analyses was set as the non-inferiority criteria. A total of 106 patients composed the ITT population: 59 and 47 allocated to 7- and 14-day groups, respectively. The PP population included 75 patients: 47 and 28 in the 7- and 14-day groups, respectively. Clinical failure occurred in 42.4% and 44.7% of the ITT population in 7- and 14-day groups, respectively, (risk difference (RD) − 2.3, 95%CI − 21.3 to 16.7), and in 46.8% and 50.0% of the PP population in 7- and 14-day groups, respectively (RD − 3.2, 95%CI − 26.6 to 20.2). Most infections were of the respiratory tract (73/68.9%) and caused by carbapenem-resistant Enterobacterales (42/39.6%). The study was interrupted before reaching planned sample size due to low recruitment rate. The OPTIMISE trial could not determine the non-inferiority of 7-day compared to 14-day therapy for severe infections caused by MDR-GNB due to early termination related to the low recruitment rate. Trial registration: NCT05210387 on January 13, 2022.
- 18 December 2024
- Published by Springer Nature in Critical Care
- Vol. 28 (1) , 1-12
Open AccessSeven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial
Shorter courses of antimicrobial therapy have been shown to be non-inferior to longer durations for the management of several infections. However, data on critically ill patients with severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB) are scarce. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we assessed the non-inferiority of 7-day versus 14-day antimicrobial therapy for patients with intensive care unit (ICU)-acquired severe infections by MDR-GNB. This was a randomised multicenter, open-label, parallel controlled, non-inferiority trial. Adult patients with severe infections by MDR-GNB initiated ≥ 48 h of ICU admission were eligible if they were hemodynamically stable and without fever > 48 h on the 7th day of appropriate antimicrobial therapy. Patients were 1:1 randomised to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14 (± 1) days. The primary outcome was clinical failure, defined as death or relapse of infection within 28 days of randomisation. An upper edge of the two-tailed 95% confidence interval (CI) of the delta between the clinical failure rate in the 7- and the 14-day lower than 10% in both intention-to-treat (ITT) and per protocol (PP) analyses was set as the non-inferiority criteria. A total of 106 patients composed the ITT population: 59 and 47 allocated to 7- and 14-day groups, respectively. The PP population included 75 patients: 47 and 28 in the 7- and 14-day groups, respectively. Clinical failure occurred in 42.4% and 44.7% of the ITT population in 7- and 14-day groups, respectively, (risk difference (RD) − 2.3, 95%CI − 21.3 to 16.7), and in 46.8% and 50.0% of the PP population in 7- and 14-day groups, respectively (RD − 3.2, 95%CI − 26.6 to 20.2). Most infections were of the respiratory tract (73/68.9%) and caused by carbapenem-resistant Enterobacterales (42/39.6%). The study was interrupted before reaching planned sample size due to low recruitment rate. The OPTIMISE trial could not determine the non-inferiority of 7-day compared to 14-day therapy for severe infections caused by MDR-GNB due to early termination related to the low recruitment rate. Trial registration: NCT05210387 on January 13, 2022.
- Open Access
- 31 October 2024
- Published by Springer Nature in Intensive Care Medicine
- Vol. 50 (12) , 2144-2145
Skin decontamination to prevent infections in the intensive care unit
- 31 October 2024
- Published by Springer Nature in Intensive Care Medicine
- Vol. 50 (12) , 2144-2145
Open AccessSkin decontamination to prevent infections in the intensive care unit